Tagged novabay

Press Release

Novel Non-antibiotic Anti-infective Successfully Treats Impetigo Patients Including 100% Infected with MRSA

 NovaBay Pharmaceuticals, Inc., is innovating a new class of drugs, known as Aganocide® compounds, that mimic the body's natural defense against infection. The Aganocides could potentially equal or exceed the utility of antibiotics. Read More
Press Release

NovaBay Pharmaceuticals Reports Status of Phase 2 Proof of Concept Clinical Trial for Viral Conjunctivitis

 Alcon and NovaBay will be analyzing the microbiological and clinical efficacy of the drug vs. placebo in all 81 adenovirus positive patients enrolled in the trial and plan to report on these analyses in early 2011. Read More
Press Release

Compounds Do Double Duty as Antimicrobials and Anticoagulants

 A study presented at this year's Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), showed a novel agent served as both an antimicrobial and anti-coagulation activity. Read More
Press Release

Novel Compound Found to Inhibit Biofilm Formation in Urinary Catheters

 Over 300,000 patients suffering from stroke and multiple sclerosis or spinal cord injuries resulting in quadriplegia or paraplegia use Foley catheters. These patients are at a daily risk for developing catheter-associated urinary tract infections. Read More